Biocept, Inc (BIOC)

Etorro trading 970x250
Biocept, Inc (BIOC) Logo

About Biocept, Inc

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company’s cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company’s Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept has research collaboration with Protean BioDiagnostics Inc. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. Address: 9955 Mesa Rim Road, San Diego, CA, United States, 92121

Biocept, Inc News and around…

Latest news about Biocept, Inc (BIOC) common stock and company :

Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression
22 Nov, 2021 Yahoo! Finance

AEGEA Biotechnologies, Inc., an innovative life science company with an extensive portfolio of next-generation nucleic acid technologies, announces that the new PCR-based COVID-19 assay it designed has been validated by Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services. This novel test is highly sensitive and specific, and can quantify a patient's SARS-CoV-2 viral load to determine the active infection level.

Busy Thanksgiving travel sparks U.S. COVID spread worries as Europe’s crisis worsens
22 Nov, 2021 FinancialContent

As Thanksgiving approaches, the U.S. death toll from COVID has now surpassed, in 2021, the total of 2020. Meanwhile, Europe leaders grow increasingly concerned.

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
22 Nov, 2021 FinancialContent

Biocept launches combined COVID-19 and influenza test to help patients and caregivers determine treatment decisions during peak flu season.

CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
18 Nov, 2021 FinancialContent

Case series shows Biocept's CNSide assay helps monitor treatment response and detects actionable biomarkers in patients with metastatic breast cancer.

Biocept Reports Third Quarter 2021 Financial Results
15 Nov, 2021 FinancialContent

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update.

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov, 2021 FinancialContent

Biotech stocks declined for the second straight week amid a broader market pullback, along withearnings news from small- and ...

Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
09 Nov, 2021 FinancialContent

Published abstract shows Biocept's Switch-Blocker technology increases the sensitivity of liquid biopsy assays for detecting rare cancer mutations.

Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
08 Nov, 2021 FinancialContent

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15, 2021. The Company will host an investor conference call to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Biocept to Present at the LD Micro Main Event on October 13
06 Oct, 2021 FinancialContent

Biocept to present at LD Micro Main Event

Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients
29 Sep, 2021 FinancialContent

Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that ...

Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
22 Sep, 2021 FinancialContent

Biocept provides on-campus COVID-19 testing to over 30 California community colleges, as students and staff return to in-person learning.

Biocept Invites You to Join Us at the Benzinga Healthcare Small Cap Conference
22 Sep, 2021 Yahoo! Finance

Detroit, Michigan--(Newsfile Corp. - September 22, 2021) - Biocept (NASDAQ: BIOC) will be presenting at the Benzinga Healthcare Small Cap Conference being held September 29-30, 2021. We invite our shareholders and all interested parties to explore healthcare small cap investment opportunities through two days of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: ...

7 of the Best Penny Stocks to Buy Coming Into Year-End
21 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months. The post 7 of the Best Penny Stocks to Buy Coming Into Year-End appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
21 Sep, 2021 FinancialContent

Biocept presents data showing ultra-sensitive Switch-Blocker technology detects rare cancer mutations at RAS-Targeted Drug Development Summit.

Biocept to Present at Four Virtual Investor Conferences in September
07 Sep, 2021 FinancialContent

Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows:

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep, 2021 FinancialContent

Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees. These inducement stock options have a grant date of August 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
24 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

This Analyst Just Made A Massive Upgrade To Their Biocept, Inc. (NASDAQ:BIOC) Earnings Forecasts
22 Aug, 2021 Yahoo! Finance

Shareholders in Biocept, Inc. ( NASDAQ:BIOC ) may be thrilled to learn that the covering analyst has just delivered a...

Friday Sector Laggards: Railroads, Diagnostics
20 Aug, 2021 FinancialContent

In trading on Friday, railroads shares were relative laggards, down on the day by about 0.2%. Helping drag down the group were shares of Freightcar America (RAIL), down about 0.8% and shares of Canadian Pacific Railway (CP) off about 0.7% on the day.

38 Stocks Moving In Friday's Mid-Day Session
20 Aug, 2021 FinancialContent

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of ...

22 Stocks Moving in Friday's Pre-Market Session
20 Aug, 2021 FinancialContent

Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it ...

Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay
19 Aug, 2021 FinancialContent

Biocept Inc(NASDAQ: BIOC) has announced new data from a study assessing its cerebrospinal fluid assay, CNSide. Data showed ...

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
19 Aug, 2021 FinancialContent

Study shows Biocept's CNSide assay detects and analyzes tumor cells in lung cancer patients, improving treatment decisions that may extend life.

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Biocept Stock Drops Despite Clocking Q2 Sales Of $12M
17 Aug, 2021 FinancialContent

Biocept Inc(NASDAQ: BIOC) reported itssecond-quarter revenues of $12 million, compared to a mere $917,471 a year ago, but ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
17 Aug, 2021 FinancialContent

Gainers Forte Biosciences (NASDAQ:FBRX) stock increased by 16.38% to $27.7 during Tuesday's pre-market session. The ...

Biocept Reports Second Quarter 2021 Financial Results
16 Aug, 2021 FinancialContent

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2021 and provides a business update.

Earnings Scheduled For August 16, 2021
16 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second ...

The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
15 Aug, 2021 FinancialContent

Biopharma stocks retreated in the week endingAug. 13, defying the optimism that was found in the broader market. Earnings ...

Biocept, Inc (BIOC) is a NASDAQ Common Stock listed in , ,

970x250